Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000927 Act: 34 Size: 675 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000832 Act: 34 Size: 28 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000767 Act: 34 Size: 15 KB 网页链接
$Sol-gel(SLGL)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001406 Act: 34 Size: 90 KB 网页链接
$Sol-gel(SLGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-24-000472 Act: 34 Size: 92 KB 网页链接
$Sol-gel(SLGL)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001178913-24-000307 Act: 34 Size: 56 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000223 Act: 34 Size: 321 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-000189 Act: 34 Size: 134 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-003816 Act: 34 Size: 32 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-003738 Act: 34 Size: 14 KB 网页链接